Novocure Ltd (OQ:NVCR)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: Forum, NO. 4 Grenville Street
Tel: N/A
IR: See website
Key People
William F. Doyle
Executive Chairman of the Board
Asaf Danziger
President, Chief Executive Officer, Director
Gabriel Gabriel Leung
Vice Chairman of the Board
Wilhelmus Groenhuysen
Chief Financial Officer
Michael J. Ambrogi
Chief Operating Officer
Todd Longsworth
General Counsel
Pritesh Shah
Chief Commercial Officer
Business Overview
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Financial Overview
For the six months ended 30 June 2019, Novocure Ltd revenues increased 41% to $160M. Net loss decreased 63% to $13.4M. Revenues reflect United States segment increase of 32% to $105.5M, Europe & Middle East & Africa (EMEA) (Region) segment increase of 39% to $45M. Lower net loss reflects Financial expenses, net decrease of 53% to $3.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.40 to -$0.14.
Employees: 598 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $7,221M as of Jun 30, 2019
Annual revenue (TTM): $294.45M as of Jun 30, 2019
EBITDA (TTM): -$10.26M as of Jun 30, 2019
Net annual income (TTM): -$40.75M as of Jun 30, 2019
Free cash flow (TTM): $19.34M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 98,176,183 as of Jul 18, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization